Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Verrica Pharmaceuticals stock

Own Verrica Pharmaceuticals stock in just a few minutes.

Verrica Pharmaceuticals Inc is a biotechnology business based in the US. Verrica Pharmaceuticals shares (VRCA) are listed on the NASDAQ and all prices are listed in US Dollars. Verrica Pharmaceuticals employs 29 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Verrica Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VRCA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Verrica Pharmaceuticals share price

Use our graph to track the performance of VRCA stocks over time.

Verrica Pharmaceuticals shares at a glance

Information last updated 2021-04-23.
52-week range$6.02 - $18.42
50-day moving average $14.63
200-day moving average $11.77
Wall St. target price$20.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.12

Buy Verrica Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Verrica Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Verrica Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -35.23%
Return on equity TTM -87.13%
Profit margin 0%
Book value $1.30
Market capitalisation $382.7 million

TTM: trailing 12 months

Shorting Verrica Pharmaceuticals shares

There are currently 1.2 million Verrica Pharmaceuticals shares held short by investors – that's known as Verrica Pharmaceuticals's "short interest". This figure is 8.2% up from 1.1 million last month.

There are a few different ways that this level of interest in shorting Verrica Pharmaceuticals shares can be evaluated.

Verrica Pharmaceuticals's "short interest ratio" (SIR)

Verrica Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Verrica Pharmaceuticals shares currently shorted divided by the average quantity of Verrica Pharmaceuticals shares traded daily (recently around 136245.25959368). Verrica Pharmaceuticals's SIR currently stands at 8.86. In other words for every 100,000 Verrica Pharmaceuticals shares traded daily on the market, roughly 8860 shares are currently held short.

However Verrica Pharmaceuticals's short interest can also be evaluated against the total number of Verrica Pharmaceuticals shares, or, against the total number of tradable Verrica Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Verrica Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Verrica Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0863% of the tradable shares (for every 100,000 tradable Verrica Pharmaceuticals shares, roughly 86 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Verrica Pharmaceuticals.

Find out more about how you can short Verrica Pharmaceuticals stock.

Verrica Pharmaceuticals share dividends

We're not expecting Verrica Pharmaceuticals to pay a dividend over the next 12 months.

Verrica Pharmaceuticals share price volatility

Over the last 12 months, Verrica Pharmaceuticals's shares have ranged in value from as little as $6.02 up to $18.42. A popular way to gauge a stock's volatility is its "beta".

VRCA.US volatility(beta: 2.36)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verrica Pharmaceuticals's is 2.3574. This would suggest that Verrica Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Verrica Pharmaceuticals overview

Verrica Pharmaceuticals Inc. , a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co. , Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications.

Frequently asked questions

What percentage of Verrica Pharmaceuticals is owned by insiders or institutions?
Currently 42.882% of Verrica Pharmaceuticals shares are held by insiders and 32.783% by institutions.
How many people work for Verrica Pharmaceuticals?
Latest data suggests 29 work at Verrica Pharmaceuticals.
When does the fiscal year end for Verrica Pharmaceuticals?
Verrica Pharmaceuticals's fiscal year ends in December.
Where is Verrica Pharmaceuticals based?
Verrica Pharmaceuticals's address is: 10 North High Street, West Chester, PA, United States, 19380
What is Verrica Pharmaceuticals's ISIN number?
Verrica Pharmaceuticals's international securities identification number is: US92511W1080
What is Verrica Pharmaceuticals's CUSIP number?
Verrica Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 92511W108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site